These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8627854)

  • 21. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma.
    Fixemer T; Remberger K; Bonkhoff H
    Prostate; 2003 Feb; 54(2):79-87. PubMed ID: 12497580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck.
    Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
    Virchows Arch; 2002 Aug; 441(2):133-42. PubMed ID: 12189502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. External beam radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate carcinoma.
    Algan O; Fosmire H; Hynynen K; Dalkin B; Cui H; Drach G; Stea B; Cassady JR
    Cancer; 2000 Jul; 89(2):399-403. PubMed ID: 10918172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression?
    Cheng L; Leibovich BC; Bergstralh EJ; Scherer BG; Pacelli A; Ramnani DM; Zincke H; Bostwick DG
    Cancer; 1999 Jun; 85(11):2455-9. PubMed ID: 10357418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
    Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF
    J Urol; 1997 Jul; 158(1):131-7. PubMed ID: 9186339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
    Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y
    Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy.
    Scherr DS; Vaughan ED; Wei J; Chung M; Felsen D; Allbright R; Knudsen BS
    J Urol; 1999 Jul; 162(1):12-6; discussion 16-7. PubMed ID: 10379729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
    Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic implications of p53 gene mutations in bladder tumors.
    Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
    J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.
    Lawton CA; Winter K; Grignon D; Pilepich MV
    J Clin Oncol; 2005 Feb; 23(4):800-7. PubMed ID: 15681524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 Alteration and chromosomal instability in prostatic high-grade intraepithelial neoplasia and concurrent carcinoma: analysis by immunohistochemistry, interphase in situ hybridization, and sequencing of laser-captured microdissected specimens.
    Al-Maghrabi J; Vorobyova L; Chapman W; Jewett M; Zielenska M; Squire JA
    Mod Pathol; 2001 Dec; 14(12):1252-62. PubMed ID: 11743048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations of p53 are common in early stage prostate cancer.
    Downing SR; Russell PJ; Jackson P
    Can J Urol; 2003 Aug; 10(4):1924-33. PubMed ID: 14503938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
    Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
    Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
    Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer.
    Koivisto PA; Rantala I
    J Pathol; 1999 Jan; 187(2):237-41. PubMed ID: 10365100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein expression of p53 and Bcl-2 has a strong correlation with radiation resistance of laryngeal squamous cell carcinoma but does not predict the radiation failure before treatment.
    Ogawa T; Shiga K; Tateda M; Saijo S; Suzuki T; Sasano H; Miyagi T; Kobayashi T
    Oncol Rep; 2003; 10(5):1461-6. PubMed ID: 12883724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.
    Grignon DJ; Caplan R; Sarkar FH; Lawton CA; Hammond EH; Pilepich MV; Forman JD; Mesic J; Fu KK; Abrams RA; Pajak TF; Shipley WU; Cox JD
    J Natl Cancer Inst; 1997 Jan; 89(2):158-65. PubMed ID: 8998185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunoreactive p53 protein in high-grade prostatic intraepithelial neoplasia.
    Humphrey PA; Swanson PE
    Pathol Res Pract; 1995 Sep; 191(9):881-7. PubMed ID: 8606869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations.
    Mottaz AE; Markwalder R; Fey MF; Klima I; Merz VW; Thalmann GN; Ball RK; Studer UE
    Prostate; 1997 Jun; 31(4):209-15. PubMed ID: 9180930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.